Compare NRIX & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | ASH |
|---|---|---|
| Founded | 2009 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Chemicals |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2020 | 2016 |
| Metric | NRIX | ASH |
|---|---|---|
| Price | $14.76 | $75.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $33.50 | ★ $82.45 |
| AVG Volume (30 Days) | ★ 3.4M | 645.3K |
| Earning Date | 10-12-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 2.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.26 | 0.43 |
| Revenue | $76,987,000.00 | ★ $1,824,000,000.00 |
| Revenue This Year | $786.93 | $3.97 |
| Revenue Next Year | N/A | $4.29 |
| P/E Ratio | ★ $4.52 | $175.77 |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $12.61 | $48.00 |
| 52 Week High | $28.23 | $79.50 |
| Indicator | NRIX | ASH |
|---|---|---|
| Relative Strength Index (RSI) | 25.08 | 55.54 |
| Support Level | $14.65 | $66.79 |
| Resistance Level | $17.47 | $78.88 |
| Average True Range (ATR) | 1.22 | 2.19 |
| MACD | -0.77 | -0.00 |
| Stochastic Oscillator | 0.23 | 43.74 |
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.